335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29060 | Christiane Jungels | Multiple | Servier | CL1-95012-001 | Trial open for recruitment | A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors | christiane.jungels@hubruxelles.be | 1 | 1 | ||
| 22824 | Anaplasic lymphoma kinase (ALK) positive | Thierry Berghmans | Multiple | Novartis | CLDK378A2303 | Trial closed | A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib | 3 | 3 | ||
| 22639 | First line metastatic | Spyridon Sideris | Kidney | Eisai Limited | CLEAR | Trial closed for recruitment | A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 29606 | Francesco Sclafani | Multiple | Novartis | CNIS793E12201 - daNIS-3 | Trial closed | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) |
francesco.sclafani@hubruxelles.be | 2 | 2 | ||
| 29424 | Participants who have histologically documented FL or DLBCL, that has relapsed or failed to respond to at least two prior systemic treatment regimens, that expresses CD20 as determined by the local laboratory, at least one bi-dimensionally measurable (?1. | Marie Maerevoet | Non-Hodgkin lymphoma | F. Hoffmann-La Roche Ltd | CO43116 | Trial closed | A phase Ib/II open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of Mosunetuzumab in combination with Tiragolumab with or without Atezolizumab in patients with relapsed or refractory b-cell non-hodgkin lymphoma | marie.maerevoet@hubruxelles.be | 1/2 | 1 | |
| 22821 | BRAF V600 mutation | Joseph Kerger | Skin | Roche | COBRIM | Trial closed for recruitment | GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma | joseph.kerger@hubruxelles.be | 3 | 3 | |
| 22637 | newly diagnosed multiple myeloma >= 70 years old |
Nathalie Meuleman | Myeloma | UZ-K.U.Leuven | COMPASS | Trial closed | COMPASS study - Comparison of different geriatric screening methods in newly diagnosed multiple myeloma patients, and assessment of therapeutic efficacy and toxicity in fit and frail patients. A multicenter observational Belgian study | nathalie.meuleman@hubruxelles.be | |||
| 28883 | Nieves Martinez Chanza | prostate | Exelixis | CONTACT 02 | Trial closed for recruitment | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | ||
| 29711 | Alain Hendlisz | Multiple | Bordet | COPERNIC | Trial open for recruitment | A study of on-treatment ctDNA changes in chemo-refractory colorectal cancer patients | alain.hendlisz@hubruxelles.be | ||||
| 22742 | colorectal cancer, metastatic or unresectable and for which standard treatments do not exist or are no longer effective. All standard chemotherapy agents (fluoropyrimidines, irinotecan and oxaliplatin) and monoclonal antibodies (bevacizumab, cetuximab an |
Alain Hendlisz | Colon | Institut Jules Bordet | CORIOLAN | Trial closed | CORIOLAN : Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advanced colorectal cancer | alain.hendlisz@hubruxelles.be | |||
| 22681 | *NTSR1 expression *Measureable disease RECIST 1.1 |
Patrick Flamen | Germ cell tumors | Ipsen | D-FR-01087-001 | Trial closed | An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors | patrick.flamen@hubruxelles.be | 1/2 | 1 | |
| 22759 | EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. | Thierry Berghmans | NSCLC | AstraZeneca | D5164C00001 ADAURA | Trial closed for recruitment | A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) | 3 | 3 | ||
| 22768 | At least one measurable lesion | Yassine Lalami | Bones - soft tissue | AstraZeneca | D5660C00004 | Trial closed | A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | yassine.lalami@hubruxelles.be | 1/2 | 1 | |
| 29677 | - Histologically proven DLBCL and associated subtypes - Relapsed or refractory disease after first-line chemoimmunotherapy - Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regime |
Marie Maerevoet | Non-Hodgkin lymphoma | Miltenyi Biomedicine GmbH | DALY 2-EU | Trial open for recruitment | A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation (M-2020-371) | marie.maerevoet@hubruxelles.be | 2 | 2 |